Form 4: Guardant Health CMO's Stock Transactions

Guardant Health's Chief Medical Officer, Craig Eagle, reported the vesting of restricted stock units and subsequent tax-related share disposition.

Summary

• Craig Eagle, Chief Medical Officer of Guardant Health, Inc. [GH], reported transactions on September 15, 2025, related to his equity compensation.
• 1,402 shares of common stock were acquired by Mr. Eagle upon the conversion of restricted stock units (RSUs).
• 711 shares of common stock were disposed of at a price of $54.79 per share to satisfy tax withholding obligations associated with the RSU vesting.
• Following these transactions, Mr. Eagle beneficially owns 37,482 shares of Guardant Health common stock.
• Additionally, Mr. Eagle holds 4,206 derivative securities in the form of restricted stock units.
• The transactions relate to a restricted stock unit award granted on June 9, 2023, of which 33% vested on June 15, 2024, with the remaining 67% scheduled to vest in equal quarterly installments over the subsequent two-year period.

Sentiment

Score: 5

Explanation: The filing details a routine insider transaction related to executive compensation, which is neutral in its immediate impact on the company's operational or financial outlook.

Positives

• The vesting of restricted stock units indicates continued equity participation and alignment of the Chief Medical Officer's interests with shareholders.
• The acquisition of common stock increases the executive's direct ownership in the company.

Negatives

• A portion of the vested shares (711 shares) was sold to cover tax liabilities, resulting in a reduction of direct beneficial ownership compared to the total vested amount.

Future Outlook

The remaining 67% of the restricted stock unit award granted on June 9, 2023, is scheduled to vest in equal quarterly installments over the next two years.

Industry Context

This filing represents a routine insider transaction, common across publicly traded companies, where executives receive equity compensation that vests over time, leading to periodic reports of share acquisitions and tax-related dispositions.

Stakeholder Impact

• Shareholders may note the Chief Medical Officer's continued equity participation and the routine nature of executive compensation transactions.

Next Steps

• The remaining 67% of the restricted stock units will vest in equal quarterly installments over the next two years.

Key Dates

Recommendation

This Form 4 details a routine insider transaction involving the vesting of restricted stock units and the subsequent sale of shares to cover tax obligations. Such transactions are standard for executive compensation and do not typically indicate a change in the company's fundamental outlook or warrant a change in investment recommendation. The executive retains a significant equity stake, suggesting continued alignment with shareholder interests.

Keywords

Guardant Health, GH, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Equity Compensation, Craig Eagle, Chief Medical Officer